Novo Nordisk A/S (NYSE:NVO) Shares Bought by King Wealth Management Group

King Wealth Management Group lifted its position in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) by 186.1% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 18,542 shares of the company's stock after buying an additional 12,061 shares during the period. King Wealth Management Group's holdings in Novo Nordisk A/S were worth $1,918,000 as of its most recent SEC filing.

Several other large investors have also made changes to their positions in the company. Pacific Center for Financial Services raised its holdings in shares of Novo Nordisk A/S by 100.0% in the 3rd quarter. Pacific Center for Financial Services now owns 270 shares of the company's stock worth $25,000 after purchasing an additional 135 shares during the period. Bell Investment Advisors Inc lifted its position in Novo Nordisk A/S by 79.9% during the 3rd quarter. Bell Investment Advisors Inc now owns 286 shares of the company's stock worth $26,000 after acquiring an additional 127 shares in the last quarter. CNB Bank purchased a new position in Novo Nordisk A/S in the 4th quarter worth approximately $26,000. Tyler Stone Wealth Management grew its position in Novo Nordisk A/S by 100.0% in the third quarter. Tyler Stone Wealth Management now owns 292 shares of the company's stock valued at $27,000 after acquiring an additional 146 shares in the last quarter. Finally, West Paces Advisors Inc. raised its stake in shares of Novo Nordisk A/S by 100.0% during the third quarter. West Paces Advisors Inc. now owns 300 shares of the company's stock valued at $27,000 after purchasing an additional 150 shares during the period. 11.54% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on NVO shares. BMO Capital Markets assumed coverage on Novo Nordisk A/S in a research note on Friday, April 12th. They set an "outperform" rating and a $163.00 price objective for the company. Morgan Stanley began coverage on shares of Novo Nordisk A/S in a research report on Tuesday, January 23rd. They set an "overweight" rating and a $120.00 price target for the company. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $160.00 price target on shares of Novo Nordisk A/S in a report on Thursday, April 18th. Finally, UBS Group assumed coverage on shares of Novo Nordisk A/S in a report on Tuesday, January 16th. They set a "neutral" rating for the company. Two research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $133.60.

Novo Nordisk A/S Stock Performance

Shares of NYSE:NVO traded down $0.24 on Friday, reaching $128.42. 3,081,075 shares of the company's stock were exchanged, compared to its average volume of 4,080,162. The business's 50-day moving average is $127.69 and its two-hundred day moving average is $114.03. The company has a quick ratio of 0.50, a current ratio of 0.70 and a debt-to-equity ratio of 0.17. Novo Nordisk A/S has a fifty-two week low of $75.56 and a fifty-two week high of $138.28. The firm has a market capitalization of $576.29 billion, a price-to-earnings ratio of 44.28, a PEG ratio of 2.00 and a beta of 0.43.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.

Want to see what other hedge funds are holding NVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novo Nordisk A/S (NYSE:NVO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.